Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Day One Biopharmaceuticals (DAWN) Interest & Investment Income: 2023-2025

Historic Interest & Investment Income for Day One Biopharmaceuticals (DAWN) over the last 3 years, with Sep 2025 value amounting to $4.6 million.

  • Day One Biopharmaceuticals' Interest & Investment Income fell 14.34% to $4.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $20.4 million, marking a year-over-year increase of 9.12%. This contributed to the annual value of $19.7 million for FY2024, which is 14.63% up from last year.
  • Day One Biopharmaceuticals' Interest & Investment Income amounted to $4.6 million in Q3 2025, which was down 2.40% from $4.7 million recorded in Q2 2025.
  • Day One Biopharmaceuticals' Interest & Investment Income's 5-year high stood at $6.1 million during Q4 2024, with a 5-year trough of $3.5 million in Q2 2023.
  • Moreover, its 3-year median value for Interest & Investment Income was $4.8 million (2023), whereas its average is $4.8 million.
  • Its Interest & Investment Income has fluctuated over the past 5 years, first rose by 20.46% in 2024, then declined by 14.34% in 2025.
  • Over the past 3 years, Day One Biopharmaceuticals' Interest & Investment Income (Quarterly) stood at $5.0 million in 2023, then increased by 20.46% to $6.1 million in 2024, then dropped by 14.34% to $4.6 million in 2025.
  • Its Interest & Investment Income stands at $4.6 million for Q3 2025, versus $4.7 million for Q2 2025 and $5.1 million for Q1 2025.